RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer - Related Studies

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

This study is currently recruiting participants.

Study NCT00629525. Last updated on February 27, 2008. Information provided by Duke University

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Hormone Refractory Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		RAD001

5	Additional drug interventions recognized in this trial
		Everolimus

6	More general drug interventions related to this trial
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		Duke University
		Novartis